Journal Article

FZJ-2021-02680

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer

Dietlein, F. ; Mueller, P. ; Kobe, C. ; Endepols, H.FZJ* ; Hohberg, M. ; Zlatopolskiy, B.FZJ* ; Krapf, P.FZJ* ; Heidenreich, A. ; Neumaier, B.FZJ* ; Drzezga, A.FZJ* ; Dietlein, M. (Corresponding author)

2021
Springer Nature Switzerland Cham

This record in other databases:    

Please use a persistent id in citations: http://hdl.handle.net/2128/28068  doi:10.1007/s11307-020-01546-0

Abstract: Purpose: PSMA imaging is frequently used for monitoring of androgen deprivation therapy(ADT) in prostate cancer. In a previous study, [18F]-JK-PSMA-7 exhibited favorable propertiesfor tumor localization after biochemical recurrence. In this retrospective study, we evaluated theperformance of [18F]-JK-PSMA-7 under ADT.Procedures: We examined the performance of [18F]-JK-PSMA-7 in 70 patients (first cohort) withincreasing or detectable PSA values under ADT (PSA G 2 ng/ml for 21/70 patients). We furtheranalyzed 58 independent patients with PSA levels G 2 ng/ml under ADT, who were imaged with[68Ga]PSMA-11 or [18F]DCFPyL (second cohort). Finally, we compared detection rates between[18F]-JK-PSMA-7, [68Ga]PSMA-11, and [18F]DCFPyL.Results: In the first cohort, we detected [18F]-JK-PSMA-7-positive lesions in 63/70 patients. Inpatients with PSA levels ≥ 2 ng/ml, the detection rate was 100 % (49/49). In patients with PSA G 2ng/ml, the detection rate was significantly lower (66.7 %, 14/21, p = 9.7 × 10−5) and dropped from85.7%(12/14, PSA levels between 0.3 and 2.0 ng/ml) to 28.6%(2/7) for PSA levels G 0.3 ng/ml (p =1.73 × 10−2). In the second cohort (PSA G 2 ng/ml), the detection rate was 79.3 % (46/58) for[68Ga]PSMA-11 or [18F]DCFPyL. Again, the detection rate was significantly higher (p = 1.1 × 10−2)for patients with PSA levels between 0.3 and 2.0 ng/ml (87.0 %, 40/46) relative to those with PSAlevels G 0.3 ng/ml (50 %, 6/12). No significant difference was found between [18F]-JK-PSMA-7 and[68Ga]PSMA-11 or [18F]DCFPyL in patients with PSA levels G 2 ng/ml (p = 0.4295).Conclusion: [18F]-JK-PSMA-7 PET showed a high detection rate in patients with PSA levels ≥0.3 ng/ml under ADT. The lower PSA threshold of 0.3 ng/ml for high detection rates wasconsistent across the three PSMA ligands. Thus, PSMA imaging is suitable for clinical follow-upof patients with increasing PSA levels under ADT.

---

Contributing Institute(s):

1. Nuklearchemie (INM-5)
2. Molekulare Organisation des Gehirns (INM-2)

Research Program(s):

1. 525 - Decoding Brain Organization and Dysfunction (POF4-525) (POF4-525)

Appears in the scientific report 2021

---

Database coverage:
; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---